Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Latest News
Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX
Annual Meetings of Stockholders
Clinical Trials
Puma is pleased to announce the following clinical trials with alisertib, an investigational drug, for small cell lung cancer (ALISCA™-Lung1) and metastatic breast cancer (ALISCA™-Breast1). For more information on each clinical trial, please click on the corresponding link below.
Our Product
FDA APPROVED TREATMENT
To Learn More
Click Here
©2017 Puma Biotechnology, Inc.